SEARCH:   Advanced

Blood, 15 December 2005, Vol. 106, No. 13, pp. 4217-4224. Prepublished online as a Blood First Edition Paper on September 6, 2005; DOI 10.1182/blood-2005-02-0563. This Article Full Text (PDF) Supplemental Figure All Versions of this Article: 2005-02-0563v1 106/13/4217    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Goodyear, O. Articles by Moss, P. A Search for Related Content PubMed PubMed Citation Articles by Goodyear, O. Articles by Moss, P. A Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 9, 2005 Accepted August 11, 2005 CD8+ T cells specific for cancer-germline gene antigens are found in many patients with multiple myeloma and their frequency correlates with disease burden Oliver Goodyear*, Karen Piper, Naeem Khan, Jane Starczynski, Prem Mahendra, Guy Pratt, and Paul A Moss Department of Haematology, CR-UK Institute for Cancer Studies, Birmingham, West Midlands, United Kingdom Heartlands Hospitals, Birmingham, West Midlands, United Kingdom Queen Elizabeth Hospital, Birmingham, West Midlands, United Kingdom * Corresponding author; email: OCG182{at}bham.ac.uk. The expression of Cancer Germ-line Antigens (CGAgs) is normally restricted to the testis but is also present in many types of malignant cells including plasma cells from patients with myeloma. As T cell immune responses to CGAg have been identified in patients with solid tumors, this may offer a novel target for immunotherapy in patients with myeloma. We have used twelve peptide epitopes from a range of CGAgs to screen for CGAg-specific T cells in blood from patients with multiple myeloma at various stages of their disease. T cells from 15 out of 37 patients responded to one or more CGAg peptides and the magnitude of the CGAg-specific CD8+ T cell response ranged between 0.0004% and 0.1% of the total CD8+ T cell pool. Serial analyses showed that these immune responses were detectable in individual patients at multiple time-points during the course of their disease. In patients undergoing treatment or disease relapse, the magnitude of the CGAg-specific T cell response was positively correlated with the level of paraprotein. Functional T cells specific for CGAgs are therefore present in a proportion of patients with multiple myeloma and offer the possibility of a novel approach for immunotherapy in this disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Condomines, D. Hose, T. Reme, G. Requirand, M. Hundemer, M. Schoenhals, H. Goldschmidt, and B. Klein Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma J. Immunol., July 15, 2009; 183(2): 832 - 840. [Abstract] [Full Text] [PDF] K. Rezvani, A. S. M. Yong, A. Tawab, B. Jafarpour, R. Eniafe, S. Mielke, B. N. Savani, K. Keyvanfar, Y. Li, R. Kurlander, et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia Blood, March 5, 2009; 113(10): 2245 - 2255. [Abstract] [Full Text] [PDF] O. C. Goodyear, G. Pratt, A. McLarnon, M. Cook, K. Piper, and P. Moss Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma Blood, October 15, 2008; 112(8): 3362 - 3372. [Abstract] [Full Text] [PDF] L.-b. Li, D. Y. M. Leung, M. J. Strand, and E. Goleva ATF2 impairs glucocorticoid receptor mediated transactivation in human CD8+ T cells Blood, September 1, 2007; 110(5): 1570 - 1577. [Abstract] [Full Text] [PDF] J. Liu, A. Hamrouni, D. Wolowiec, V. Coiteux, K. Kuliczkowski, D. Hetuin, A. Saudemont, and B. Quesnel Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway Blood, July 1, 2007; 110(1): 296 - 304. [Abstract] [Full Text] [PDF] M. Condomines, D. Hose, P. Raynaud, M. Hundemer, J. De Vos, M. Baudard, T. Moehler, V. Pantesco, M. Moos, J.-F. Schved, et al. Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis J. Immunol., March 1, 2007; 178(5): 3307 - 3315. [Abstract] [Full Text] [PDF] D. Atanackovic, J. Arfsten, Y. Cao, S. Gnjatic, F. Schnieders, K. Bartels, G. Schilling, C. Faltz, C. Wolschke, J. Dierlamm, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation Blood, February 1, 2007; 109(3): 1103 - 1112. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020